Suppr超能文献

盐皮质激素受体依赖性和非依赖性保钾利尿剂对纤溶平衡的不同影响。

Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.

作者信息

Ma Ji, Albornoz Francisco, Yu Chang, Byrne Daniel W, Vaughan Douglas E, Brown Nancy J

机构信息

Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN, USA.

出版信息

Hypertension. 2005 Aug;46(2):313-20. doi: 10.1161/01.HYP.0000174327.53863.86. Epub 2005 Jul 5.

Abstract

This study tests the hypothesis that spironolactone influences plasminogen activator inhibitor-1 (PAI-1) concentrations through mineralocorticoid receptor antagonism rather than through changes in potassium. Effects of spironolactone (50 mg per day) and triamterene (50 mg per day) on fibrinolytic balance were compared in 18 normotensive and 20 hypertensive subjects pretreated with hydrochlorothiazide (HCTZ; 12.5 mg per day). Blood pressure and serum potassium were similar in spironolactone and triamterene treatment groups. The effect of the 2 drugs on the renin-angiotensin-aldosterone system was also similar. In contrast, spironolactone and triamterene exerted opposing effects on PAI-1 antigen (P=0.006 for drug effect). In normotensive subjects, triamterene (from 10.1+/-7.8 to 16.9+/-9.9 ng/mL at 9 am, P=0.019; from 7.6+/-5.4 to 11.5+/-7.3 ng/mL at 11 am, P=0.027; from 9.3+/-7.7 to 13.7+/-8.5 ng/mL for average of all time points, P=0.054) but not spironolactone significantly increased PAI-1 antigen. In hypertensive subjects, spironolactone significantly decreased PAI-1 antigen (from 22.0+/-23.4 to 16.7+/-19.0 ng/mL at 10 am, P=0.041; from 17.5+/-21.7 to 12.7+/-16.8 ng/mL at 11 am, P=0.043; from 20.3+/-22.6 to 16.6+/-19.7 ng/mL for average of all time points, P=0.014), whereas there was no effect of triamterene. Only spironolactone significantly decreased the molar ratio of PAI-1 to tissue-type plasminogen activator (t-PA) in hypertensive subjects. By regression analysis, predictors of mean PAI-1 response were spironolactone versus triamterene (P=0.014), hypertension (P=0.002), and PAI-1 response to HCTZ (P=0.019), with a trend for aldosterone (P=0.061). Mineralocorticoid receptor antagonism prevents the effect of activation of the renin-angiotensin-aldosterone system on PAI-1 antigen in normotensive subjects and improves fibrinolytic balance in hypertensive subjects through a potassium-independent mechanism.

摘要

本研究检验了以下假设

螺内酯通过盐皮质激素受体拮抗作用而非通过钾离子变化来影响纤溶酶原激活物抑制剂-1(PAI-1)浓度。在18名血压正常和20名高血压受试者中,比较了螺内酯(每日50毫克)和氨苯蝶啶(每日50毫克)对纤溶平衡的影响,这些受试者均预先接受了氢氯噻嗪(HCTZ;每日12.5毫克)治疗。螺内酯组和氨苯蝶啶组的血压和血清钾水平相似。这两种药物对肾素-血管紧张素-醛固酮系统的作用也相似。相比之下,螺内酯和氨苯蝶啶对PAI-1抗原产生了相反的作用(药物效应P = 0.006)。在血压正常的受试者中,氨苯蝶啶(上午9点时从10.1±7.8纳克/毫升升至16.9±9.9纳克/毫升,P = 0.019;上午11点时从7.6±5.4纳克/毫升升至11.�±7.3纳克/毫升,P = 0.027;所有时间点的平均值从9.3±7.7纳克/毫升升至13.7±8.5纳克/毫升,P = 0.054)但不是螺内酯显著增加了PAI-1抗原。在高血压受试者中,螺内酯显著降低了PAI-1抗原(上午10点时从22.0±23.4纳克/毫升降至16.7±19.0纳克/毫升,P = 0.041;上午11点时从17.5±21.7纳克/毫升降至12.7±16.8纳克/毫升,P = 0.043;所有时间点的平均值从20.3±22.6纳克/毫升降至16.6±19.7纳克/毫升,P = 0.014),而氨苯蝶啶没有作用。只有螺内酯显著降低了高血压受试者中PAI-1与组织型纤溶酶原激活物(t-PA)的摩尔比。通过回归分析,PAI-1平均反应的预测因素是螺内酯与氨苯蝶啶(P = 0.014)、高血压(P = 0.002)以及PAI-1对HCTZ的反应(P = 0.019),醛固酮有一定趋势(P = 0.061)。盐皮质激素受体拮抗作用可防止肾素-血管紧张素-醛固酮系统激活对血压正常受试者PAI-1抗原的影响,并通过不依赖钾离子的机制改善高血压受试者的纤溶平衡。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验